IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

IDO1 Inhibitor RY103 Suppresses Trp-GCN2-Mediated Angiogenesis and Counters Immunosuppression in Glioblastoma

Glioma is characterized by strong immunosuppression and excessive angiogenesis. Based on existing reports, it can be speculated that the resistance to anti-angiogenic drug vascular endothelial growth factor A (VEGFA) antibody correlates to the induction of novel immune checkpoint indoleamine 2,3-dio...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Zikang Xing, Xuewen Li, Zhen Ning Tony He, Xin Fang, Heng Liang, Chunxiang Kuang, Aiying Li, Qing Yang
Format:	Artikel
Sprache:	English
Veröffentlicht:	MDPI AG 2024-06-01
Schriftenreihe:	Pharmaceutics
Schlagworte:	glioma angiogenesis indoleamine 2,3-dioxygenase 1 tryptophan depletion general control nonderepressible 2
Online Zugang:	https://www.mdpi.com/1999-4923/16/7/870

Ähnliche Einträge

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
von: V. A. Kozlov, et al.
Veröffentlicht: (2017-07-01)

On the nonredundant roles of TDO2 and IDO1
von: Paolo ePuccetti
Veröffentlicht: (2014-10-01)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
von: Ganiyu Olatunbosun Arinola, et al.
Veröffentlicht: (2023-01-01)

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
von: Chiara Suvieri, et al.
Veröffentlicht: (2024-11-01)

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past
von: Yu Yao, et al.
Veröffentlicht: (2021-02-01)

Tryptophan-degrading enzymes in tumoral immune resistance
von: Nicolas van Baren, et al.
Veröffentlicht: (2016-11-01)

Association of Indoleamine 2,3-Dioxygenase (IDO) Activity with Outcome after Cardiac Surgery in Adult Patients
von: Andrea Stieger, et al.
Veröffentlicht: (2024-06-01)

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges
von: Peng X, et al.
Veröffentlicht: (2022-08-01)

Serum neopterin concentrations and tryptophan degradation pattern in patients with late stage larynx carcinoma
von: Engin Ayse Basak, et al.
Veröffentlicht: (2017-08-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
von: Cemil Bilir, M.D., et al.
Veröffentlicht: (2017-07-01)

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders
von: Adrian Mor, et al.
Veröffentlicht: (2024-07-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
von: Eleonora Panfili, et al.
Veröffentlicht: (2023-04-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
von: Chuan Zhou, et al.
Veröffentlicht: (2020-03-01)

Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic Immunosuppression
von: Mengna Wang, et al.
Veröffentlicht: (2025-02-01)

Pharmacological Targets of Kaempferol Within Inflammatory Pathways—A Hint Towards the Central Role of Tryptophan Metabolism
von: Stefanie Hofer, et al.
Veröffentlicht: (2020-02-01)

Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
von: Florent Peyraud, et al.
Veröffentlicht: (2022-01-01)

The Potential Role of Cannabinoids in Modulating Serotonergic Signaling by Their Influence on Tryptophan Metabolism
von: Dietmar Fuchs, et al.
Veröffentlicht: (2010-08-01)

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia
von: Christine L Miller, et al.
Veröffentlicht: (2004-04-01)

In vitro Effects of Nigella sativa Seeds Extracts on Stimulated Peripheral Blood Mononuclear Cells
von: Winkler Christiana, et al.
Veröffentlicht: (2008-02-01)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T Cells in Mammals
von: Ursula eGrohmann, et al.
Veröffentlicht: (2015-02-01)

Systemic tryptophan homeostasis
von: Simon Klaessens, et al.
Veröffentlicht: (2022-09-01)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
von: Li-Ping Zhao, et al.
Veröffentlicht: (2023-01-01)

1-MT inhibits the invasion of CBP-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function
von: Huihan Ma, et al.
Veröffentlicht: (2020-09-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
von: Thiara Manuele Alves de Souza, et al.
Veröffentlicht: (2022-04-01)

Indoleamine 2,3-Dioxygenase as a Therapeutic Target for Alzheimer’s Disease and Geriatric Depression
von: Karl Savonije, et al.
Veröffentlicht: (2023-05-01)

An exploratory study of neopterin and kynurenine pathway in pterygium
von: Kilicarslan Bilge, et al.
Veröffentlicht: (2019-08-01)

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
von: A. Marijne Heeren, et al.
Veröffentlicht: (2018-07-01)

Nattokinase mitigated dextran sulfate sodium-induced chronic colitis by regulating microbiota and suppressing tryptophan metabolism via inhibiting IDO-1
von: Lvqi Zhou, et al.
Veröffentlicht: (2020-12-01)

Deletion of indoleamine 2,3 dioxygenase (Ido)1 but not Ido2 exacerbates disease symptoms of MOG35-55-induced experimental autoimmune encephalomyelitis
von: Lisa A. Wetzel, et al.
Veröffentlicht: (2020-08-01)

IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma
von: Hongmei Liu, et al.
Veröffentlicht: (2022-07-01)

Targeting the IDO1 pathway in cancer: from bench to bedside
von: Ming Liu, et al.
Veröffentlicht: (2018-08-01)

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
von: Concetta Elisa Onesti, et al.
Veröffentlicht: (2019-07-01)

Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
von: Pilvi Maliniemi, et al.
Veröffentlicht: (2017-03-01)

Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma
von: Dongquan Xiang, et al.
Veröffentlicht: (2023-06-01)

Kynurenines as a Novel Target for the Treatment of Malignancies
von: Adrian Mor, et al.
Veröffentlicht: (2021-06-01)

The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
von: Jacques C. Mbongue, et al.
Veröffentlicht: (2015-09-01)

The role of tryptophan in Chlamydia trachomatis persistence
von: Li Wang, et al.
Veröffentlicht: (2022-08-01)

Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents
von: Hui Wen, et al.
Veröffentlicht: (2019-06-01)

AncPhore: A versatile tool for anchor pharmacophore steered drug discovery with applications in discovery of new inhibitors targeting metallo-β-lactamases and indoleamine/tryptophan 2,3-dioxygenases
von: Qingqing Dai, et al.
Veröffentlicht: (2021-07-01)

Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism
von: Heinz Zoller, et al.
Veröffentlicht: (2015-06-01)